Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.70 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.70 |
| ▸ | BUB1 | O43683 | 1/20 | 0.70 |
| ▸ | PRKACG | P22612 | 1/20 | 0.70 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.70 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.70 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538654 | 0.92 | MAPK14 (0.68) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3408212 | 0.90 | MAPK14 (0.72) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3405352 | 0.90 | MAPK14 (0.73) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3426997 | 0.89 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL29795179 | 0.89 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3406084 | 0.88 | MAPK14 (0.75) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3411773 | 0.88 | MAPK14 (0.69) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3412151 | 0.87 | MAPK14 (0.74) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3427110 | 0.87 | MAPK14 (0.70) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3533718 | 0.87 | MAPK14 (0.70) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654235-B1 | 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-7838540-B2 | 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20070161684-A1 | 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | SIMITHKLINE BEECHMAN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161684-A1 | 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | MAPK1, MAPK3, MAPKAPK2 | MAPK14 34/4885CYP2C9 914/4885MAPK11 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.